BEGONIA Trial: A Plain-English Overview of What It Established

At a glance

Parameter	Detail
N	949 (randomized)
Intervention	Flibanserin 100 mg oral, once nightly
Comparator	Matching placebo, once nightly
Duration	24 weeks of treatment
Primary endpoint	Change from baseline in number of satisfying sexual events (SSEs) per 28 days
Key co-endpoints	Sexual desire (eDiary), Female Sexual Function Index (FSFI) desire domain, Female Sexual Distress Scale-Revised (FSDS-R) Item 13
Key result	Statistically significant improvement in desire and distress; SSE increase was numerically higher but co-primary analyses supported efficacy

What Question Did BEGONIA Ask?

By 2010, HSDD was one of the most common sexual complaints among premenopausal women, yet no pharmacotherapy existed for it. Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist originally developed as an antidepressant, had shown signal in earlier Phase II work suggesting it could increase sexual desire through central serotonergic and dopaminergic modulation.

The BEGONIA trial asked a straightforward question: does flibanserin 100 mg nightly, compared to placebo, meaningfully improve sexual desire and reduce associated distress in premenopausal women who meet DSM-IV-TR criteria for HSDD?

Who Was Enrolled (and Who Wasn't)

BEGONIA recruited 949 premenopausal women across North American sites. Key inclusion criteria:

• Age 18 and older, stable menstrual cycles
• DSM-IV-TR diagnosis of generalized, acquired HSDD
• Stable, monogamous sexual relationship for at least one year
• Willing to attempt sexual activity at least twice monthly

Notable exclusions removed women with other primary sexual disorders (arousal disorder, pain disorders), those on antidepressants or other CNS-active medications, women with major depression, and anyone consuming more than moderate alcohol. These restrictions are important for interpreting generalizability: the trial population was otherwise healthy, not on psychiatric medications, and in a relationship context.

Baseline demographics showed a mean age of approximately 36 years. Participants had been experiencing low desire for roughly 5 years on average, indicating established rather than transient complaints.

What Participants Actually Did

After a 4-week baseline screening (including a single-blind placebo run-in to eliminate high placebo responders), 949 women were randomized 1:1 to flibanserin 100 mg or placebo taken at bedtime for 24 weeks. Bedtime dosing was chosen specifically to mitigate somnolence and dizziness.

Participants recorded desire, arousal, and sexual events daily using an electronic diary (eDiary). Validated instruments (FSFI, FSDS-R) were administered at scheduled visits. This dual-capture method (daily diary plus periodic validated scales) provided both granular day-to-day data and standardized clinical endpoints.

Results: What the Numbers Actually Show

The HealthRX.com BEGONIA Efficacy Summary

The trial used a co-primary endpoint structure. Below is the magnitude of treatment effects reported:

Context for these numbers: the gain of approximately 0.5 to 1 additional satisfying sexual event per month over placebo is modest in absolute terms. The desire score improvement was small on a 10-point scale. But for the distress endpoint, the reduction was clinically meaningful to patients who reported it had been a persistent source of relationship and personal distress.

Placebo Response

The placebo group improved too, which is typical in sexual medicine trials where simply being asked about desire daily, receiving clinical attention, and enrolling with a partner can change behavior. The 4-week placebo run-in was designed to filter out easy placebo responders, yet the effect remained substantial.

Time Course

Effects on desire separated from placebo by approximately week 4 and were maintained through week 24. This contrasts with pharmacological agents that show immediate onset and suggests flibanserin's mechanism involves gradual neuroadaptation rather than acute pharmacological action, consistent with its serotonergic receptor profile.

Safety and Tolerability

Discontinuation due to adverse events was 9.6% for flibanserin vs. 3.7% for placebo. No serious safety signals (syncope, severe hypotension) emerged in this trial at the frequency later flagged with alcohol co-administration.

The FDA label for Addyi ultimately included a boxed warning about hypotension and syncope with alcohol, a risk identified primarily in dedicated pharmacokinetic interaction studies rather than in BEGONIA itself.

Limitations the Authors Acknowledged

1. Generalizability constraints. Women on antidepressants, those with comorbid depression, and those without stable partners were excluded. Real-world HSDD populations are more complex.

2. Measurement sensitivity. The SSE endpoint counts events but may not capture the subjective quality improvement patients value most. Desire is inherently difficult to quantify with a single numeric diary score.

3. Effect size. The differences, while statistically significant, were small in absolute magnitude. Whether an additional 0.5-1 SSE per month constitutes clinical meaningfulness was debated extensively at FDA advisory committee hearings.

4. Duration. 24 weeks provides medium-term data. Longer-term maintenance and what happens upon discontinuation required separate open-label extension data.

5. Enrichment design. The placebo run-in removed early placebo responders, potentially inflating the apparent drug-placebo separation compared to a real-world prescription scenario.

Where BEGONIA Fits in the Bigger Picture

BEGONIA was one of three randomized Phase III trials (alongside DAISY and VIOLET) that formed the FDA approval package for flibanserin in August 2015. After two prior rejections (2010 to 2013) citing insufficient efficacy and safety concerns, the resubmission with additional data, including BEGONIA, received a narrow advisory committee vote (18-6 in favor).

The International Society for the Study of Women's Sexual Health (ISSWSH) consensus guidelines subsequently included flibanserin as a treatment option for premenopausal HSDD, while noting the modest effect sizes. The European Medicines Agency never approved flibanserin, citing an unfavorable benefit-risk ratio.

What This Means for Clinical Practice Today

Prescribers considering flibanserin should set expectations clearly: the trial data support a real but modest improvement in desire and distress. Patients who respond tend to notice changes over 4-8 weeks, not immediately. The bedtime dosing is mandatory (not a suggestion), alcohol must be avoided completely, and the REMS program requires prescriber certification.

For patients who have tried psychoeducation, relationship therapy, or who have no modifiable contributors to low desire, BEGONIA provides the evidence that flibanserin does outperform placebo. It does not provide evidence of large effect sizes or rapid onset.

Frequently asked questions

›How many extra satisfying sexual events did flibanserin produce per month?

Approximately 0.5 to 1 additional satisfying sexual event per 28-day cycle compared to placebo. The flibanserin group gained about 2.5 SSEs from baseline versus 1.7 in the placebo group.

›Was the BEGONIA trial conducted in premenopausal or postmenopausal women?

BEGONIA enrolled exclusively premenopausal women. Separate trials (SNOWDROP) studied postmenopausal populations, and the initial FDA approval was limited to premenopausal HSDD.

›What dose of flibanserin was used in BEGONIA?

100 mg taken orally once daily at bedtime. Earlier dose-finding studies tested 25 mg, 50 mg, and 100 mg; the 100 mg bedtime dose showed the best efficacy-tolerability balance.

›Why is flibanserin taken at bedtime instead of on demand?

Flibanserin causes dizziness and somnolence. Bedtime dosing allows these effects to occur during sleep. It also reflects the drug's mechanism: it produces gradual neurochemical shifts over weeks, not acute effects timed to sexual activity.

›What were the most common side effects in BEGONIA?

Dizziness (11.4%), somnolence (11.2%), and nausea (10.4%) were the three most frequently reported adverse events exceeding placebo rates.

›Did BEGONIA study flibanserin with alcohol?

No. The trial excluded heavy drinkers and did not specifically test alcohol interactions. The severe hypotension risk with alcohol was identified in separate pharmacokinetic studies and led to the boxed warning on the FDA label.

›How long did it take to see results in the BEGONIA trial?

Separation from placebo on desire measures became apparent around week 4 and was maintained through the 24-week treatment period. Patients who see no benefit by 8 weeks are unlikely to respond.

›Is flibanserin approved in Europe?

No. The European Medicines Agency reviewed flibanserin and did not grant marketing authorization, citing an insufficient benefit-risk profile given the modest efficacy and CNS side-effect burden.

›How does BEGONIA compare to the other flibanserin key trials?

BEGONIA, DAISY, and VIOLET were all Phase III trials with similar designs in premenopausal HSDD. Results were consistent across the three: statistically significant but modest improvements in desire and distress with the same safety profile.

›Can flibanserin be prescribed to women on antidepressants?

The FDA label contraindicates use with moderate-to-strong CYP3A4 inhibitors. SSRIs and SNRIs were excluded from BEGONIA. Given flibanserin's serotonergic mechanism, co-administration with serotonergic antidepressants raises theoretical concerns and lacks safety data from controlled trials.

References

1. Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the BEGONIA trial. J Sex Med. 2012;9(2):535-545. PubMed
2. U.S. Food and Drug Administration. Addyi (flibanserin) prescribing information. 2015. FDA Label
3. Goldstein I, Kim NN, Clayton AH, et al. Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc. 2017;92(1):114-128. PubMed
4. Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453-462. PubMed
5. Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633-640. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial